Trial reportNature medicine2022
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.
3 registry-linked trialsOpen access · bronzeAbstract readClinical Trial
In one paragraph
Trial report in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 202 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
202citing papers in PubMed, 5 pooled it
31.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicenter Phase 2 Study to Identify of the Optimal Neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)
Phase II Study of Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
OMIT Trial: Omitting Therapeutic Lymph Node Dissection in Patients With Stage IIIB/C Melanoma and Major Pathological Response in the Index Lymph Node After Neoadjudvant Immunotherapy
Who cites it
202 citing papers in PubMed, 5 syntheses or guidelines pooled it, 332 citations in OpenAlex.
- Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort.Annals of oncology : official journal of the European Society for Medical Oncology · 2026Guideline
- Adjuvant immune checkpoint inhibitors across solid tumors: a meta-analysis of phase II-III randomized trials.Frontiers in oncology · 2026Pooled it
- Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis.Journal for immunotherapy of cancer · 2025Pooled it
- Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology · 2025Guideline
- Adverse events of neoadjuvant combination immunotherapy for resectable cancer patients: a systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Accuracy of Index Lymph Node Pathology in Predicting Overall Response to Neoadjuvant Immunotherapy for Clinical Stage III Melanoma: Results From the Prospective NeoACTIVATE Arm C (NCT03554083) Substudy.Annals of surgical oncology · 2026Trial
- Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.Nature medicine · 2026Trial
- Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial.Nature cancer · 2026Trial
- Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.Nature medicine · 2025Trial
- Economic Evaluation of Inguinal Versus Ilio-inguinal Lymphadenectomy for Patients with Stage III Metastatic Melanoma to Groin Lymph Nodes: Evidence from the EAGLE FM Randomized Trial.Annals of surgical oncology · 2025Trial
- Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial).Nature cancer · 2025Trial
- Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.Cancer cell · 2024Trial
- Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.Nature communications · 2024Trial
- Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.Nature medicine · 2024Trial
- Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2023Trial
- IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.The Journal of experimental medicine · 2023Trial
- Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.The New England journal of medicine · 2023Trial
- Exploring uncertainties in melanoma management: a Spanish multidisciplinary Delphi consensus.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).Nature medicine · 2026Article
- The Adjuvant-Phase Dilemma After Neoadjuvant Chemoimmunotherapy in Resectable NSCLC: Evidence and Response-Guided Strategies.Cancers · 2026Review
142 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
38 authors at 9 institutions in 3 countries.
Irene L M ReijersDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Alexander M Menzies *Melanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia.
Alexander C J van Akkooi *Melanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia.
Judith M Versluis *Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Noëlle M J van den Heuvel *Department of Psychosocial research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Robyn P M SawMelanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-3354-806X
Thomas E PenningtonMelanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia.
Ellen KapiteijnDepartment of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
Astrid A M van der VeldtDepartments of Medical Oncology and Radiology & Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
Karijn P M SuijkerbuijkDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Geke A P HospersDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0002-3047-7892
Elisa A RozemanDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Willem M C KlopDepartment of Head and Neck Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Winan J van HoudtDepartment of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Karolina SikorskaDepartment of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Jos A van der HageDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0001-9040-1323
Dirk J GrünhagenDepartment of Surgical Oncology and Gastrointestinal Surgery, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0001-8293-6002
Michel W WoutersDepartment of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-6173-0662
Arjen J WitkampDepartment of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.
Charlotte L ZuurDepartment of Head and Neck Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Judith M LijnsveltDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Alejandro Torres AcostaDepartment of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Lindsay G Grijpink-OngeringDepartment of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Maria GonzalezMelanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia.
Katarzyna JóźwiakInstitute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane, Neuruppin, Germany.
Carolien BiermanDepartment of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Kerwin F ShannonMelanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0001-8538-3132
Sydney Ch'ngMelanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia.
Andrew J ColebatchMelanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia.
Andrew J SpillaneMelanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-9520-0181
John B A G HaanenDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-5884-7704
Robert V RawsonMelanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia.
Bart A van de WielDepartment of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Lonneke V van de Poll-FranseDepartment of Psychosocial research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Richard A ScolyerMelanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-8991-0013
Annelies H BoekhoutDepartment of Psychosocial research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Georgina V LongMelanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0001-8894-3545
Christian U BlankDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. c.blank@nki.nl.ORCID http://orcid.org/0000-0002-7945-5846
The Netherlands Cancer Institute · NLThe University of Sydney · AULeiden University Medical Center · NLUniversity Medical Center Utrecht · NLErasmus MC · NLErasmus MC Cancer Institute · NLMedizinische Hochschule Brandenburg Theodor Fontane · DETilburg University · NLUniversity Medical Center Groningen · NL
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoadjuvant ipilimumab and nivolumab induces high pathologic response rates (pRRs) in clinical stage III nodal melanoma, and pathologic response is strongly associated with prolonged relapse-free survival (RFS). The PRADO extension cohort of the OpACIN-neo trial ( NCT02977052 ) addressed the feasibility and effect on clinical outcome of using pathologic response after neoadjuvant ipilimumab and nivolumab as a criterion for further treatment personalization. In total, 99 patients with clinical stage IIIb-d nodal melanoma were included and treated with 6 weeks of neoadjuvant ipilimumab 1 mg kg
Indexed as
MelanomaSkin NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCutaneous Malignant MelanomaHumansIpilimumabNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingNivolumabQuality of LifeIpilimumabNivolumab
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.